Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, Vandamme P, Piérard D.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00590-18. doi: 10.1128/AAC.00590-18. Print 2018 Sep.

2.

"Switching partners": Piperacillin-avibactam is a highly potent combination against multidrug-resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis isolates.

Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM.

J Clin Microbiol. 2019 Jun 5. pii: JCM.00181-19. doi: 10.1128/JCM.00181-19. [Epub ahead of print]

PMID:
31167848
3.

Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F; China Antimicrobial Surveillance Network (CHINET) Study Group.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02431-18. doi: 10.1128/AAC.02431-18. Print 2019 Apr.

PMID:
30617091
4.

Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.

Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.

5.

Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.

Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.

Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.

PMID:
30831233
6.

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.

7.

Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01093-17. doi: 10.1128/JCM.01093-17. Print 2018 Feb.

8.

Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.

Grupper M, Sutherland C, Nicolau DP.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00875-17. doi: 10.1128/AAC.00875-17. Print 2017 Oct.

9.

Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA.

ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.

10.

In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.

Massip C, Mathieu C, Gaudru C, Miaut V, Floch P, Oswald E, Segonds C, Guet-Revillet H.

J Antimicrob Chemother. 2019 Feb 1;74(2):525-528. doi: 10.1093/jac/dky423. No abstract available.

PMID:
30312409
11.

ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.

Ortiz de la Rosa JM, Nordmann P, Poirel L.

J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939. doi: 10.1093/jac/dkz149.

PMID:
31225611
12.

Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species.

Everaert A, Coenye T.

Antimicrob Resist Infect Control. 2016 Nov 16;5:44. eCollection 2016.

13.

Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid.

Correa-Ruiz A, Girón R, Buendía B, Medina-Pascual MJ, Valenzuela C, López-Brea M, Sáez-Nieto JA.

Enferm Infecc Microbiol Clin. 2013 Dec;31(10):649-54. doi: 10.1016/j.eimc.2012.12.001. Epub 2013 Mar 23.

PMID:
23528342
14.

Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.

Meyer K, Santarossa M, Danziger LH, Wenzler E.

Hosp Pharm. 2017 Mar;52(3):221-228. doi: 10.1310/hpj5203-221.

15.

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam.

Gangcuangco LM, Clark P, Stewart C, Miljkovic G, Saul ZK.

Case Rep Infect Dis. 2016;2016:1520404. Epub 2016 Oct 12.

16.

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01858-17. doi: 10.1128/AAC.01858-17. Print 2017 Dec.

17.
18.

In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.

Mazer DM, Young C, Kalikin LM, Spilker T, LiPuma JJ.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00766-17. doi: 10.1128/AAC.00766-17. Print 2017 Sep.

19.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.

PMID:
26003469
20.

Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.

Rac H, Stover KR, Wagner JL, King ST, Warnock HD, Barber KE.

Infect Dis Ther. 2017 Dec;6(4):507-513. doi: 10.1007/s40121-017-0176-8. Epub 2017 Oct 20.

Supplemental Content

Support Center